

Piodiab[®]

Pioglitazone Hydrochloride




achieving goals
...saving lives

...Saving lives


Piodiab[®]
Pioglitazone Hydrochloride



Pioglitazone decreases FPG significantly and rapidly⁶



Pioglitazone has a sustained effect on the reduction of HbA_{1c} for over 2 years⁴



Pioglitazone has a sustained effect on glycemic control for over 2 years⁴

Piodiab[®]
Pioglitazone Hydrochloride

- ▶ Targets the three defects of type 2 diabetes^{1,2,3}
- ▶ Improves and preserves β -cell function⁵
- ▶ Significantly and rapidly reduces FPG⁶
- ▶ Has a sustained effect on the reduction of HbA_{1c}⁴
- ▶ Has a positive effect on lipid profiles^{8,9}
- ▶ Significantly lowers the risk of death, MI, or stroke¹⁰
- ▶ Has no restriction on concomitant use with insulin

References:

1. BARNETT A.H. Redefining the Role of Thiazolidinediones in the Management of Type 2 Diabetes. *Vascular Health and Risk Management* 2009;5: 141–151 2. GASTALDELLI A. et al. The Effect of Pioglitazone on the Liver: Role of Adiponectin. *Diabetes Care* Vol 29, Number 10, October 2006 3. GASTALDELLI A. et al. Thiazolidinediones Improve β -cell Function in Type 2 Diabetic Patients. *Am J Physiol Endocrinol Metab* 292: E871–E883, 2007 4. TAN M.H. et al. Comparison of Pioglitazone and Gliclazide in Sustaining Glycemic Control Over 2 Years in Patients With Type 2 Diabetes. *Diabetes Care* Vol 28, Number 3, March 2005 5. HANEFELD M. Pioglitazone and sulfonylurea: effectively treating type 2 diabetes. *Int J Clin Pract*, June 2007, 61, (Suppl. 153), 20–27 6. ARONOFF S. et al. Pioglitazone Hydrochloride Monotherapy Improves Glycemic Control in the Treatment of Patients With Type 2 Diabetes: A 6-month randomized placebo-controlled dose-response study. *Diabetes Care* Vol 23, Number 11, November 2000 7. KINTSCHER U. Pharmacological Differences of Glitazones: Does Peroxisome Proliferator-Activated Receptor- Activation Make the Difference?. *Journal of the American College of Cardiology* Vol 52, No. 10, 2008 8. GOLDBERG R.B. et al. A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia. *Diabetes Care* Vol 28, Number 7, July 2005 9. BOYLE P.J. et al. Effects of Pioglitazone and Rosiglitazone on Blood Lipid Levels and Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Retrospective Review of Randomly Selected Medical Records. *Clin Ther*. 2002 Mar;24(3):378-96 10. LINCOFF A.M. et al. Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials. *JAMA*. 2007;298(10):1180-1188

Before prescribing please consult physicians' circular.

® Registered trade name

Piodiab[®] manufactured by **BPI**



Benta Pharma Industries - Dbayeh, Lebanon

Piodiab[®]
Pioglitazone Hydrochloride



achieving goals
...saving lives

PD 100F LE 5-2010